Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia

被引:2
|
作者
Alkhatabi, Heba [1 ,2 ]
Bin Saddeq, Haneen Abdulfattah [3 ]
Alyamani, Luay [4 ]
Shinawi, Thoraia [1 ]
Yasin, Elrashed B. [5 ]
Alserihi, Raed [1 ,6 ]
Felimban, Raed [1 ,6 ]
Tayeb, Hossam H. [1 ,6 ]
Mimani, Rawan [2 ]
Alalla, Zainab [2 ]
Abu-Elmagd, Muhammad [2 ]
Abuzenadah, Adel [1 ,7 ]
机构
[1] King Abdulaziz Univ, Fac Appl Med Sci, Dept Med Lab Technol, Jeddah 80200, Saudi Arabia
[2] King Abdulaziz Univ, Ctr Excellence Genom Med Res CEGMR, Jeddah 80200, Saudi Arabia
[3] King Abdullah Med City, Mecca 24246, Saudi Arabia
[4] King Saud Bin Abdelaziz Univ Hlth Sci, Coll Med, Basic Med Sci Dept, Jeddah 80200, Saudi Arabia
[5] King Abdulaziz Univ, Fac Appl Med Sci, Dept Med Lab Technol, Rabigh 25732, Saudi Arabia
[6] King Abdulaziz Univ, Ctr Innovat Personalized Med CIPM, Jeddah 80200, Saudi Arabia
[7] King Abdulaziz Univ, King Fahad Med Res Ctr KFMRC, Jeddah 80200, Saudi Arabia
关键词
IDH1; IDH2; AML; ALL; ACUTE MYELOID-LEUKEMIA; IDH2; MUTATIONS; FREQUENCY;
D O I
10.3390/genes12121963
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Different forms of human cancer show mutations for isocitrate dehydrogenases 1 and 2 (IDH1/2). Mutation of these genes can cause aberrant methylation of the genome CpG islands (CGIs), which leads to an increase of suppressed oncogenes transcription or repression of active tumor suppressor gene transcription. This study aimed to identify the prevalence of IDH1/2 mutations in acute leukemia patients. The study cohort included 43 AML patients and 30 childhood ALL patients, from whom DNA bone marrow samples were taken. The alteration hotspots in codons IDH1 (R132) and IDH2 (R172 and R140) were examined via direct sequencing. Mutations in IDH1 were detected in 7 out of 43 (16.2%) AML patients; 5 of them occurred at codon R132. The other two mutations included a single-nucleotide polymorphism, which affected codon G105 in one patient. However, no mutation was detected in the IDH2 in any of the patients. Moreover, no mutations were detected in either IDH1 or IDH2 in ALL patients. The dominance of IDH1 mutations in AML, which was 16%, emphasizes the existence of the mutation in our population. On the other hand, IDH2 mutation was observed to be less frequent in both illnesses. Due to the limitation of using a small sample size, larger cohort screening is recommended to determine their usefulness as prognostic indicators.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors-Recent Advances, Challenges and Future Prospects
    Kowalczyk, Adrian
    Zarychta, Julia
    Lejman, Monika
    Latoch, Eryk
    Zawitkowska, Joanna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [22] Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia
    Koszarska, Magdalena
    Bors, Andras
    Feczko, Angela
    Meggyesi, Nora
    Batai, Arpad
    Csomor, Judit
    Adam, Emma
    Kozma, Andras
    Orban, Tamas I.
    Lovas, Nora
    Sipos, Andrea
    Karaszi, Eva
    Dolgos, Janos
    Fekete, Sandor
    Reichardt, Judit
    Lehoczky, Eniko
    Masszi, Tamas
    Tordai, Attila
    Andrikovics, Hajnalka
    LEUKEMIA & LYMPHOMA, 2013, 54 (05) : 1028 - 1035
  • [23] Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
    Xiaoyan Liu
    Yuping Gong
    Biomarker Research, 7
  • [24] Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission
    Chou, W-C
    Peng, K-Y
    Lei, W-C
    Ko, B-S
    Tsay, W.
    Kuo, C-H
    Tien, H-F
    LEUKEMIA, 2012, 26 (03) : 527 - 529
  • [25] Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation
    Heiblig, Mael
    Hachem-Khalife, Sabine
    Willekens, Christophe
    Micol, Jean-Baptiste
    Paci, Angelo
    Penard-Lacronique, Virginie
    de Bottona, Stephane
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2020, 5 (06): : 421 - 428
  • [26] The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia
    W-C Chou
    W-C Lei
    B-S Ko
    H-A Hou
    C-Y Chen
    J-L Tang
    M Yao
    W Tsay
    S-J Wu
    S-Y Huang
    S-C Hsu
    Y-C Chen
    Y-C Chang
    K-T Kuo
    F-Y Lee
    M-C Liu
    C-W Liu
    M-H Tseng
    C-F Huang
    H-F Tien
    Leukemia, 2011, 25 : 246 - 253
  • [27] Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
    Sadudee Chotirat
    Wanna Thongnoppakhun
    Orathai Promsuwicha
    Chetsada Boonthimat
    Chirayu U Auewarakul
    Journal of Hematology & Oncology, 5
  • [28] Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
    Chotirat, Sadudee
    Thongnoppakhun, Wanna
    Promsuwicha, Orathai
    Boonthimat, Chetsada
    Auewarakul, Chirayu U.
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2012, 5
  • [29] Combining Isocitrate Dehydrogenase Inhibitors With Existing Regimens in Acute Myeloid Leukemia An Evolving Treatment Landscape
    Lachowiez, Curtis
    DiNardo, Courtney D.
    Stein, Etyan
    CANCER JOURNAL, 2022, 28 (01) : 21 - 28
  • [30] Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT
    Mohty, Razan
    Bazarbachi, Abdul Hamid
    Labopin, Myriam
    Esteve, Jordi
    Kroeger, Nicolaus
    Cornelissen, Jan J.
    Blaise, Didier
    Socie, Gerard
    Maury, Sebastien
    Ganser, Arnold
    Gedde-Dahl, Tobias
    von dem Borne, Peter
    Bourhis, Jean Henri
    Bulabois, Claude Eric
    Yakoub-Agha, Ibrahim
    Pabst, Caroline
    Nguyen, Stephanie
    Chevallier, Patrice
    Huynh, Anne
    Bazarbachi, Ali
    Nagler, Arnon
    Ciceri, Fabio
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2024, 59 (11) : 1534 - 1541